Yoshino T - Search Results

1

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.

Siena S, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, Fakih M, Elez E, Rodriguez J, Ciardiello F, Komatsu Y, Esaki T, Chung K, Wainberg Z, Sartore-Bianchi A, Saxena K, Yamamoto E, Bako E, Okuda Y, Shahidi J, Grothey A, Yoshino T; DESTINY-CRC01 investigators. Siena S, et al. Among authors: yoshino t. Lancet Oncol. 2021 Jun;22(6):779-789. doi: 10.1016/S1470-2045(21)00086-3. Epub 2021 May 4. Lancet Oncol. 2021. PMID: 33961795 Clinical Trial.

2

Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.

Yoshino T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yamaguchi Y, Hasuike N, Yamazaki K, Machida N, Ono H. Yoshino T, et al. Jpn J Clin Oncol. 2007 Sep;37(9):686-91. doi: 10.1093/jjco/hym091. Epub 2007 Aug 24. Jpn J Clin Oncol. 2007. PMID: 17720736

3

Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.

Machida N, Yoshino T, Boku N, Hironaka S, Onozawa Y, Fukutomi A, Yamazaki K, Yasui H, Taku K, Asaka M. Machida N, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2008 Oct;38(10):689-94. doi: 10.1093/jjco/hyn086. Jpn J Clin Oncol. 2008. PMID: 18845522

4

A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer.

Muro K, Yoshino T, Doi T, Shirao K, Takiuchi H, Hamamoto Y, Watanabe H, Yang BB, Asahi D. Muro K, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2009 May;39(5):321-6. doi: 10.1093/jjco/hyp016. Epub 2009 Mar 14. Jpn J Clin Oncol. 2009. PMID: 19287023 Clinical Trial.

5

Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin.

Yasui H, Yoshino T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yamazaki K, Taku K, Kojima T, Machida N. Yasui H, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2009 May;39(5):315-20. doi: 10.1093/jjco/hyp014. Jpn J Clin Oncol. 2009. PMID: 19403734

6

Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.

Mochizuki S, Yoshino T, Kojima T, Fuse N, Ikematsu H, Minashi K, Yano T, Tahara M, Kaneko K, Doi T, Koike K, Ohtsu A. Mochizuki S, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2010 Oct;40(10):933-7. doi: 10.1093/jjco/hyq058. Epub 2010 May 21. Jpn J Clin Oncol. 2010. PMID: 20494948

7

Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancer.

Doi T, Tahara M, Yoshino T, Yamazaki K, Tamura T, Yamada Y, Yang BB, Oliner KS, Otani S, Asahi D. Doi T, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2011 Feb;41(2):210-6. doi: 10.1093/jjco/hyq229. Epub 2010 Dec 17. Jpn J Clin Oncol. 2011. PMID: 21169348

8

FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study).

Mishima H, Oba K, Sakamoto J, Muro K, Yoshino T, Hyodo I, Maehara Y. Mishima H, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2012 Feb;42(2):134-8. doi: 10.1093/jjco/hyr180. Epub 2011 Dec 12. Jpn J Clin Oncol. 2012. PMID: 22167662 Free PMC article. Clinical Trial.

9

Early clinical outcomes of anal squamous cell carcinoma treated with concurrent chemoradiotherapy with 5-Fluorouracil plus mitomycin C in Japanese patients: experience at a single institution.

Satake H, Yoshino T, Sasaki T, Bando H, Yoda Y, Ikematsu H, Kojima T, Fuse N, Zenda S, Doi T, Kaneko K, Ohtsu A. Satake H, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2012 Sep;42(9):861-4. doi: 10.1093/jjco/hys093. Epub 2012 Jun 19. Jpn J Clin Oncol. 2012. PMID: 22717459

10

TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial.

Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Sugimoto N, Tsuji Y, Moriwaki T, Esaki T, Hamada C, Tanase T, Ohtsu A. Yoshino T, et al. Lancet Oncol. 2012 Oct;13(10):993-1001. doi: 10.1016/S1470-2045(12)70345-5. Epub 2012 Aug 28. Lancet Oncol. 2012. PMID: 22951287 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,058 results

Search Page